mitoxantrone has been researched along with Leukemia, Myeloid in 187 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine." | 9.05 | Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 8.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer." | 7.74 | Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007) |
| "We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 7.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone." | 7.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 7.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 6.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties." | 6.65 | Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984) |
| "A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine." | 5.05 | Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984) |
| "The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy." | 4.82 | Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. ( Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR, 2003) |
| "This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer." | 3.74 | Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| "To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)." | 3.69 | Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 3.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 3.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "In a phase II study, patients with chronic myelogenous leukemia in blast crisis (CML-BC) were treated with intravenous (IV) mitoxantrone (5 mg/m2 per day given over 30 min x 5 days and high-dose arabinosylcytosine (ara-C) (3 g/m2 IV q 12 h x 6)." | 3.67 | Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. ( Heinemann, V; Meyn, RE; Murray, D; Plunkett, W; Walters, R, 1988) |
| "Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone." | 3.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985) |
| " GO at a dosage of 3 mg/m2 was administered as a 2-h intravenous infusion on days 1 and 14, cytarabine at 100 mg/m2 on days 1-7, and mitoxantrone at 12 mg/m2 on days 1-3." | 2.73 | Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. ( Carluccio, P; Giannoccaro, M; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G; Spinosa, G, 2007) |
| "Overall and recurrence-free survival were 18 and 35%; 30 and 20%; 36 and 30%, respectively." | 2.73 | [The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults]. ( Anchukova, LV; Domnikova, NP; Gavrilova, LV; Golubeva, ME; Isaev, VG; Kaplanov, KD; Khlevnaia, NV; Khoroshko, ND; Khuazheva, NK; Kliasova, GA; Konstantinova, TS; Korobkin, AV; Kravchenko, SK; Kulikov, SM; Lapin, VA; Loginov, AB; Maksimov, AG; Mal'tsev, VI; Medvedeva, LI; Men'shakova, SN; Miliutina, GI; Moskov, VI; Obidina, NA; Parovichnikova, EN; Pilipenko, GI; Ploskikh, MA; Porokhina, OV; Pristupa, AS; Rekhtman, GB; Ryzhko, VV; Samoĭlova, OS; Savchenko, VG; Sokolov, AN; Sokolova, IV; Tumakov, VA; Zagoskina, TP; Ziuzgin, IS, 2007) |
| "The MTD for GMTZ in combination with cytarabine and mitoxantrone was 3 mg/m(2) while the MTD in combination with cytarabine and l-asparaginase was 2 mg/m(2)." | 2.73 | Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. ( Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008) |
| " Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease." | 2.72 | Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. ( de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006) |
| "Splenomegaly was associated with a lower CR rate (P < ." | 2.71 | Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. ( Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW, 2005) |
| " This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship." | 2.71 | Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. ( Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E, 2005) |
| " Serial blood samples for pharmacokinetic studies were obtained in 38 children over a 24-h period following cytotoxin treatment with or without CsA on days 1 and 4." | 2.70 | Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. ( Becton, DL; Bomgaars, L; Chang, MN; Dahl, GV; Lacayo, NJ; Lauer, SJ; Lum, BL; Ravindranath, Y; Sikic, BI; Weinstein, H, 2002) |
| "The clinical significance of complex chromosome aberrations for adults with acute myeloid leukaemia (AML) was assessed in 920 patients with de novo AML who were karyotyped and treated within the German AML Cooperative Group (AMLCG) trials." | 2.70 | Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. ( Büchner, T; Fonatsch, C; Haase, D; Haferlach, T; Heinecke, A; Hiddemann, W; Löffler, H; Sauerland, MC; Schlegelberger, B; Schoch, C; Staib, P, 2001) |
| " However, some trials showed that increasing the dosage of anthracyclines within induction therapy improved treatment outcome substantially." | 2.70 | Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. ( Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H, 2002) |
| "Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome." | 2.69 | A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. ( Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL, 2000) |
| "To compare the antileukemic efficacy of idarubicin and mitoxantrone in elderly patients with acute myeloid leukemia (AML) and to evaluate the feasibility of autologous transplantation using PBSC after consolidation in those with a good performance status, 160 patients (median age 69 years), with AML at diagnosis, 118 of them with de novo AML and 42 with AML secondary to myelodysplastic syndrome or toxic exposure (sAML), received induction treatment with idarubicin, 8 mg/m2/day or mitoxantrone, 7 mg/m2/day, on days 1, 3, and 5, both combined with VP-16, 100 mg/m2/day on days 1 to 3 and cytarabine (araC), 100 mg/m2/day, on days 1 to 7." | 2.69 | Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with ( Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R, 1999) |
| "Although cytosine arabinoside (AraC) represents the most effective single agent in the treatment of adults with acute myeloid leukemia (AML) when given at doses exceeding 200 to 500 mg per application, its optimal dosage is still a matter of controversial discussion." | 2.69 | Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. ( Aul, C; Bartholomäus, A; Bettelheim, P; Büchner, T; Hiddemann, W; Kern, W; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R; Wörmann, B, 1998) |
| "Intensification of treatment for acute myeloid leukemia (AML) in adult patients resulted in a substantial improvement in long-term prognosis." | 2.69 | Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study. ( Büchner, T; Kessler, T; Schumacher, A; van de Loo, J; Wewers, D, 1998) |
| " No difference in toxicity was observed between the two dosage regimens." | 2.68 | A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. ( Ahmed, T; Beer, M; Case, DC; Damon, L; Feldman, EJ; Linker, C; Ries, C; Rugo, H; Seiter, K, 1997) |
| "Twenty-two patients with previously treated acute myeloid leukemia (AML) received salvage chemotherapy with mitoxantrone, 5 mg/m2/d on days 1 to 3, etoposide, 70 mg/m2/d on days 1 to 5, and enocitabine, 170 mg/m2/d on days 1 to 7 (BHAC-ME)." | 2.68 | [Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group]. ( Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H, 1995) |
| " For consolidation with NOVE, rhGM-CSF was given according to the same dosage schedule." | 2.67 | Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. ( Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B, 1993) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 2.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties." | 2.65 | Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984) |
| "Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL." | 2.42 | Recent advances in pediatric acute lymphoblastic and myeloid leukemia. ( Ravindranath, Y, 2003) |
| "Bacterial bloodstream infections were the most frequent followed by respiratory tract infections." | 1.91 | Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "State-of-art of aggressive treatment of acute myeloid leukemia (AML) in patients older than 60 years is one of the least satisfactory topics of present-day hematology." | 1.33 | Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. ( Brychtova, Y; Buchtova, I; Doubek, M; Mayer, J; Palasek, I, 2005) |
| "Molecular relapse was detected in two patients by RQ-PCR four and six weeks, respectively before hematologic relapse occurred." | 1.33 | The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. ( Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C, 2005) |
| "Neutropenia was present in 74." | 1.32 | Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. ( Creutzig, U; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Reinhardt, D; Varwig, D, 2004) |
| "To report a 71-year-old woman with acute myelogenous leukemia in remission who developed orbital granulocytic sarcoma." | 1.30 | Orbital granulocytic sarcoma in an elderly patient. ( Remulla, HD; Rubin, PA; Watkins, LM, 1997) |
| "Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells." | 1.29 | High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. ( Bhalla, K; Bullock, G; Grant, S; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Tang, C; Tourkina, E, 1993) |
| " Further studies are needed to explore the potential impact on response and/or toxicity and the requirement of a pharmacokinetic directed adjustment of drug dosage in clinical trials." | 1.29 | New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ( Hiddemann, W; Kamischke, A; Kaufmann, CC; Schleyer, E; Unterhalt, M, 1994) |
| "AMH resembling acute megakaryoblastic leukemia may be seen transiently after treatment of AML." | 1.28 | Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia. ( Farhi, DC; Rosenthal, NS, 1991) |
| "Nine children with juvenile chronic myelogenous leukemia (JCML) were diagnosed in an 8-year period from 1977 to 1984." | 1.27 | The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. ( Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS, 1987) |
| "To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)." | 1.27 | Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (10.16) | 18.7374 |
| 1990's | 76 (40.64) | 18.2507 |
| 2000's | 82 (43.85) | 29.6817 |
| 2010's | 9 (4.81) | 24.3611 |
| 2020's | 1 (0.53) | 2.80 |
| Authors | Studies |
|---|---|
| Walti, CS | 2 |
| Halpern, AB | 3 |
| Xie, H | 2 |
| Kiem, ES | 2 |
| Chung, EL | 2 |
| Schonhoff, KG | 2 |
| Huebner, EM | 3 |
| Delaney, C | 2 |
| Liu, C | 2 |
| Pergam, SA | 2 |
| Cheng, GS | 2 |
| Kimball, LE | 2 |
| Leisenring, WM | 2 |
| Boeckh, M | 2 |
| Walter, RB | 3 |
| Hill, JA | 2 |
| Othus, M | 1 |
| Buckley, SA | 1 |
| Pogosova-Agadjanyan, EL | 1 |
| Orlowski, KF | 1 |
| Scott, BL | 1 |
| Becker, PS | 1 |
| Hendrie, PC | 1 |
| Chen, TL | 1 |
| Percival, MM | 1 |
| Estey, EH | 1 |
| Stirewalt, DL | 1 |
| Amadori, S | 6 |
| Suciu, S | 5 |
| Stasi, R | 2 |
| Salih, HR | 1 |
| Selleslag, D | 1 |
| Muus, P | 3 |
| De Fabritiis, P | 3 |
| Venditti, A | 3 |
| Ho, AD | 5 |
| Lübbert, M | 1 |
| Thomas, X | 10 |
| Latagliata, R | 1 |
| Halkes, CJ | 1 |
| Falzetti, F | 1 |
| Magro, D | 1 |
| Guimaraes, JE | 1 |
| Berneman, Z | 2 |
| Specchia, G | 3 |
| Karrasch, M | 1 |
| Fazi, P | 3 |
| Vignetti, M | 2 |
| Willemze, R | 4 |
| de Witte, T | 3 |
| Marie, JP | 6 |
| Krumbholz, M | 1 |
| Jung, R | 1 |
| Bradtke, J | 1 |
| Reinhardt, D | 3 |
| Stachel, D | 1 |
| Metzler, M | 1 |
| Pérez-García, A | 1 |
| Brunet, S | 3 |
| Berlanga, JJ | 1 |
| Tormo, M | 2 |
| Nomdedeu, J | 1 |
| Guardia, R | 3 |
| Ribera, JM | 3 |
| Heras, I | 1 |
| Llorente, A | 2 |
| Hoyos, M | 1 |
| Esteve, J | 2 |
| Besalduch, J | 2 |
| Bueno, J | 2 |
| Sierra, J | 3 |
| Gallardo, D | 1 |
| van Vliet, MJ | 1 |
| Tissing, WJ | 1 |
| Rings, EH | 1 |
| Koetse, HA | 1 |
| Stellaard, F | 1 |
| Kamps, WA | 1 |
| de Bont, ES | 1 |
| Mandelli, F | 3 |
| Petti, MC | 2 |
| Meloni, G | 1 |
| Marmont, F | 1 |
| Labar, B | 1 |
| Di Raimondo, F | 1 |
| Liso, V | 3 |
| Ferrara, F | 1 |
| Baila, L | 1 |
| Zittoun, R | 2 |
| McHayleh, W | 1 |
| Sehgal, R | 1 |
| Redner, RL | 1 |
| Raptis, A | 1 |
| Agha, M | 1 |
| Natale, J | 1 |
| Luong, TM | 1 |
| Schlesselman, JJ | 1 |
| Foon, KA | 1 |
| Boyiadzis, M | 1 |
| Guo, M | 1 |
| Hu, KX | 1 |
| Yu, CL | 1 |
| Sun, QY | 1 |
| Qiao, JH | 1 |
| Wang, DH | 1 |
| Liu, GX | 1 |
| Sun, WJ | 1 |
| Wei, L | 1 |
| Sun, XD | 1 |
| Huang, YJ | 1 |
| Qiao, JX | 1 |
| Dong, Z | 1 |
| Ai, HS | 1 |
| Advani, AS | 1 |
| Shadman, M | 1 |
| Ali-Osman, F | 1 |
| Barker, A | 1 |
| Rybicki, L | 2 |
| Kalaycio, M | 4 |
| Sekeres, MA | 1 |
| de Castro, CM | 1 |
| Diehl, LF | 1 |
| Moore, JO | 6 |
| Beaven, A | 1 |
| Copelan, E | 1 |
| Sobecks, R | 1 |
| Talea, P | 1 |
| Rizzieri, DA | 2 |
| Guan, XQ | 1 |
| Xu, L | 1 |
| Ke, ZY | 1 |
| Huang, LB | 1 |
| Zhang, XL | 1 |
| Zhang, YC | 1 |
| Luo, XQ | 1 |
| Larson, SM | 1 |
| Campbell, NP | 1 |
| Huo, D | 1 |
| Artz, A | 1 |
| Zhang, Y | 1 |
| Gajria, D | 1 |
| Green, M | 1 |
| Weiner, H | 1 |
| Daugherty, C | 1 |
| Odenike, O | 1 |
| Godley, LA | 1 |
| Hyjek, E | 1 |
| Gurbuxani, S | 1 |
| Thirman, M | 1 |
| Sipkins, D | 1 |
| Van Besien, K | 1 |
| Larson, RA | 3 |
| Stock, W | 1 |
| Kostrzewa-Nowak, D | 1 |
| Bieg, B | 1 |
| Paine, MJ | 1 |
| Wolf, CR | 1 |
| Tarasiuk, J | 1 |
| Saini, L | 1 |
| Minden, MD | 1 |
| Schuh, AC | 1 |
| Yee, KW | 1 |
| Schimmer, AD | 1 |
| Gupta, V | 1 |
| Atenafu, EG | 1 |
| Murray, C | 1 |
| Nixon, S | 1 |
| Brandwein, JM | 1 |
| Gibson, AD | 1 |
| Handa, H | 1 |
| Motohashi, S | 1 |
| Isozumi, K | 1 |
| Komatsumoto, S | 1 |
| Nara, M | 1 |
| Schaich, M | 2 |
| Illmer, T | 2 |
| Aulitzky, W | 1 |
| Bodenstein, H | 1 |
| Clemens, M | 1 |
| Neubauer, A | 2 |
| Repp, R | 1 |
| Schäkel, U | 1 |
| Soucek, S | 1 |
| Wandt, H | 2 |
| Ehninger, G | 4 |
| Anderson, JE | 2 |
| Kopecky, KJ | 3 |
| Willman, CL | 2 |
| Head, D | 1 |
| O'Donnell, MR | 1 |
| Luthardt, FW | 2 |
| Norwood, TH | 1 |
| Chen, IM | 1 |
| Balcerzak, SP | 1 |
| Johnson, DB | 1 |
| Appelbaum, FR | 5 |
| Abbott, BL | 1 |
| Colapietro, AM | 1 |
| Barnes, Y | 1 |
| Marini, F | 2 |
| Andreeff, M | 2 |
| Sorrentino, BP | 1 |
| Ravindranath, Y | 3 |
| Wrzesien-Kus, A | 3 |
| Robak, T | 3 |
| Jamroziak, K | 1 |
| Wierzbowska, A | 2 |
| Dmoszynska, A | 2 |
| Adamczyk-Cioch, M | 1 |
| Kuliczkowski, K | 2 |
| Mazur, G | 2 |
| Holowiecki, J | 1 |
| Konopka, L | 1 |
| Maj, S | 1 |
| Marianska, B | 1 |
| Zawilska, K | 1 |
| He, XY | 2 |
| Pohlman, B | 2 |
| Lichtin, A | 3 |
| Schlenk, RF | 4 |
| Benner, A | 2 |
| Hartmann, F | 2 |
| del Valle, F | 2 |
| Weber, C | 1 |
| Pralle, H | 2 |
| Fischer, JT | 3 |
| Gunzer, U | 2 |
| Pezzutto, A | 1 |
| Weber, W | 2 |
| Grimminger, W | 1 |
| Preiss, J | 1 |
| Hensel, M | 1 |
| Fröhling, S | 2 |
| Döhner, K | 3 |
| Haas, R | 3 |
| Döhner, H | 5 |
| Maurillo, L | 2 |
| Buccisano, F | 2 |
| Del Poeta, G | 3 |
| Mazzone, C | 2 |
| Tamburini, A | 2 |
| Del Principe, MI | 2 |
| Consalvo, MI | 2 |
| Cudillo, L | 1 |
| Picardi, A | 1 |
| Franchi, A | 1 |
| Lo-Coco, F | 1 |
| Coco, FL | 1 |
| Lehrnbecher, T | 2 |
| Varwig, D | 1 |
| Kaiser, J | 1 |
| Klingebiel, T | 1 |
| Creutzig, U | 2 |
| Hiçsönmez, G | 1 |
| Cetin, M | 1 |
| Tuncer, AM | 1 |
| Yenicesu, I | 1 |
| Aslan, D | 1 |
| Ozyürek, E | 1 |
| Unal, S | 1 |
| Kröger, N | 1 |
| Damon, L | 2 |
| Zander, AR | 1 |
| Derigs, G | 1 |
| Ferrante, P | 1 |
| Demirer, T | 2 |
| Rosti, G | 1 |
| Graf, M | 1 |
| Reif, S | 1 |
| Hecht, K | 1 |
| Pelka-Fleischer, R | 1 |
| Pfister, K | 1 |
| Nuessler, V | 1 |
| Schmetzer, H | 1 |
| Marczak, A | 1 |
| Krykowski, E | 1 |
| Júźwiak, Z | 1 |
| Löfgren, C | 1 |
| Paul, C | 1 |
| Aström, M | 1 |
| Hast, R | 1 |
| Hedenius, M | 1 |
| Lerner, R | 1 |
| Liliemark, J | 1 |
| Nilsson, I | 1 |
| Rödjer, S | 1 |
| Simonsson, B | 2 |
| Stockelberg, D | 1 |
| Tidefelt, U | 1 |
| Björkholm, M | 1 |
| Perel, Y | 2 |
| Auvrignon, A | 1 |
| Leblanc, T | 2 |
| Michel, G | 2 |
| Vannier, JP | 2 |
| Dalle, JH | 1 |
| Gandemer, V | 1 |
| Schmitt, C | 1 |
| Mèchinaud, F | 1 |
| Lamagnere, JP | 1 |
| Piguet, Ch | 1 |
| Couillaud, G | 1 |
| Pautard, B | 1 |
| Baruchel, A | 2 |
| Leverger, G | 2 |
| Kern, W | 6 |
| Voskova, D | 1 |
| Schoch, C | 3 |
| Schnittger, S | 3 |
| Hiddemann, W | 11 |
| Haferlach, T | 4 |
| Oriol, A | 2 |
| Pedro, C | 1 |
| Sánchez, JM | 1 |
| Batlle, M | 1 |
| Vivancos, P | 1 |
| Carreras, E | 1 |
| Vilà, JM | 1 |
| Julià, A | 1 |
| Montserrat, E | 1 |
| Feliu, E | 2 |
| Daenen, S | 1 |
| van der Holt, B | 1 |
| Verhoef, GE | 1 |
| Löwenberg, B | 2 |
| Wijermans, PW | 1 |
| Huijgens, PC | 1 |
| van Marwijk Kooy, R | 1 |
| Schouten, HC | 1 |
| Kramer, MH | 1 |
| Ferrant, A | 1 |
| van den Berg, E | 1 |
| Steijaert, MM | 1 |
| Verdonck, LF | 1 |
| Sonneveld, P | 2 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Farag, SS | 1 |
| Ruppert, AS | 2 |
| Mrózek, K | 2 |
| Mayer, RJ | 2 |
| Stone, RM | 3 |
| Carroll, AJ | 2 |
| Powell, BL | 3 |
| Pettenati, MJ | 2 |
| Koduru, PR | 1 |
| Stamberg, J | 1 |
| Baer, MR | 2 |
| Block, AW | 1 |
| Vardiman, JW | 2 |
| Kolitz, JE | 2 |
| Schiffer, CA | 5 |
| Bloomfield, CD | 3 |
| Benderra, Z | 1 |
| Faussat, AM | 1 |
| Sayada, L | 1 |
| Perrot, JY | 1 |
| Chaoui, D | 1 |
| Legrand, O | 1 |
| Staib, P | 3 |
| Staltmeier, E | 1 |
| Neurohr, K | 1 |
| Cornely, O | 1 |
| Reiser, M | 1 |
| Schinköthe, T | 1 |
| Elhamri, M | 3 |
| Chelghoum, Y | 2 |
| Reman, O | 3 |
| Arnaud, P | 2 |
| Raffoux, E | 3 |
| Le, QH | 2 |
| Tavernier, E | 1 |
| Dombret, H | 5 |
| Michallet, M | 4 |
| Raaijmakers, MH | 1 |
| de Grouw, EP | 1 |
| Heuver, LH | 1 |
| van der Reijden, BA | 2 |
| Jansen, JH | 1 |
| Scheper, RJ | 3 |
| Scheffer, GL | 3 |
| de Witte, TJ | 1 |
| Raymakers, RA | 1 |
| Naito, K | 1 |
| Ohnishi, K | 1 |
| Lech-Marańda, E | 1 |
| Pluta, A | 1 |
| Wawrzyniak, E | 1 |
| Krawczyńska, A | 1 |
| Kiebiński, M | 1 |
| Wach, M | 1 |
| Hellmann, A | 1 |
| Baran, W | 1 |
| Hołowiecki, J | 1 |
| Kyrcz-Krzemień, S | 1 |
| Grosicki, S | 1 |
| Shanks, RH | 1 |
| Flowers, JL | 1 |
| Colvin, OM | 1 |
| Adams, DJ | 1 |
| Le, Q | 1 |
| Botton, Sd | 2 |
| Pautas, C | 2 |
| Dreyfus, F | 4 |
| Dhedin, N | 1 |
| Vekhoff, A | 2 |
| Troncy, J | 1 |
| Pigneux, A | 1 |
| Revel, Td | 1 |
| Travade, P | 2 |
| Thiebaut, A | 1 |
| Guerci, A | 2 |
| Fenaux, P | 6 |
| Chevallier, P | 1 |
| Roland, V | 1 |
| Mahé, B | 1 |
| Juge-Morineau, N | 1 |
| Dubruille, V | 1 |
| Guillaume, T | 1 |
| Vigouroux, S | 1 |
| Moreau, P | 1 |
| Milpied, N | 1 |
| Garand, R | 1 |
| Avet-Loiseau, H | 1 |
| Harousseau, JL | 2 |
| Marcucci, G | 1 |
| Maharry, K | 1 |
| Edwards, CG | 1 |
| Sterling, LJ | 1 |
| Lemez, P | 1 |
| Urbánek, V | 1 |
| Doubek, M | 1 |
| Palasek, I | 1 |
| Brychtova, Y | 1 |
| Buchtova, I | 1 |
| Mayer, J | 2 |
| Stiefelhagen, P | 1 |
| Scholl, C | 1 |
| Eiwen, K | 1 |
| Rao, A | 1 |
| Hills, RK | 1 |
| Stiller, C | 1 |
| Gibson, BE | 1 |
| de Graaf, SS | 1 |
| Hann, IM | 2 |
| O'Marcaigh, A | 1 |
| Wheatley, K | 3 |
| Webb, DK | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Mueller, S | 1 |
| Holdenrieder, S | 1 |
| Stieber, P | 1 |
| Schalhorn, A | 1 |
| Braess, J | 2 |
| Nagel, D | 1 |
| Seidel, D | 1 |
| Büchner, T | 8 |
| Berdel, WE | 1 |
| Serve, HL | 1 |
| Kienast, J | 1 |
| Tchinda, J | 1 |
| Reichle, A | 1 |
| Lengfelder, E | 1 |
| Ludwig, WD | 3 |
| Aul, C | 3 |
| Eimermacher, H | 2 |
| Balleisen, L | 1 |
| Sauerland, MC | 2 |
| Heinecke, A | 2 |
| Wörmann, B | 7 |
| Tomizawa, D | 1 |
| Tabuchi, K | 1 |
| Kinoshita, A | 1 |
| Hanada, R | 1 |
| Kigasawa, H | 1 |
| Tsukimoto, I | 1 |
| Tsuchida, M | 1 |
| Jehn, U | 2 |
| Lefrère, F | 1 |
| Adamo, F | 1 |
| Fillet, G | 3 |
| Nobile, F | 1 |
| Ricciuti, F | 1 |
| Leone, G | 1 |
| Rizzoli, V | 1 |
| Montanaro, M | 1 |
| Beeldens, F | 1 |
| Zimmermann, M | 1 |
| Graf, N | 1 |
| Hermann, J | 1 |
| Niemeyer, CM | 1 |
| Reiter, A | 1 |
| Ritter, J | 1 |
| Dworzak, M | 1 |
| Stary, J | 1 |
| Le Deley, MC | 1 |
| Suzan, F | 1 |
| Cutuli, B | 1 |
| Delaloge, S | 1 |
| Shamsaldin, A | 1 |
| Linassier, C | 1 |
| Clisant, S | 1 |
| de Vathaire, F | 1 |
| Hill, C | 1 |
| Ngirabacu, MC | 1 |
| Ravoet, C | 1 |
| Dargent, JL | 1 |
| Meuleman, N | 1 |
| Ahmad, I | 1 |
| Ysebrant, L | 1 |
| Bennani, J | 1 |
| André, M | 1 |
| Bron, D | 1 |
| de Revel, T | 2 |
| Terré, C | 1 |
| Corront, B | 1 |
| Gardin, C | 1 |
| Quesnel, B | 1 |
| Cordonnier, C | 4 |
| Bourhis, JH | 1 |
| Preudhomme, C | 1 |
| Castaigne, S | 1 |
| Pastore, D | 1 |
| Carluccio, P | 1 |
| Spinosa, G | 1 |
| Giannoccaro, M | 1 |
| Rizzi, R | 1 |
| Mestice, A | 1 |
| Weisser, M | 1 |
| Haferlach, C | 1 |
| Spagnoli, A | 1 |
| Panetta, P | 1 |
| Neri, B | 1 |
| Ottaviani, L | 1 |
| Fraboni, D | 1 |
| Sarlo, C | 1 |
| Parovichnikova, EN | 1 |
| Savchenko, VG | 1 |
| Isaev, VG | 1 |
| Sokolov, AN | 1 |
| Kulikov, SM | 1 |
| Kliasova, GA | 1 |
| Ryzhko, VV | 1 |
| Kravchenko, SK | 1 |
| Khoroshko, ND | 1 |
| Konstantinova, TS | 1 |
| Zagoskina, TP | 1 |
| Ziuzgin, IS | 1 |
| Rekhtman, GB | 1 |
| Moskov, VI | 1 |
| Sokolova, IV | 1 |
| Anchukova, LV | 1 |
| Lapin, VA | 1 |
| Loginov, AB | 1 |
| Tumakov, VA | 1 |
| Korobkin, AV | 1 |
| Miliutina, GI | 1 |
| Samoĭlova, OS | 1 |
| Mal'tsev, VI | 1 |
| Pristupa, AS | 1 |
| Men'shakova, SN | 1 |
| Domnikova, NP | 1 |
| Gavrilova, LV | 1 |
| Obidina, NA | 1 |
| Porokhina, OV | 1 |
| Kaplanov, KD | 1 |
| Medvedeva, LI | 1 |
| Khuazheva, NK | 1 |
| Pilipenko, GI | 1 |
| Golubeva, ME | 1 |
| Maksimov, AG | 1 |
| Ploskikh, MA | 1 |
| Khlevnaia, NV | 1 |
| O'Brien, MM | 1 |
| Taub, JW | 1 |
| Chang, MN | 2 |
| Massey, GV | 1 |
| Stine, KC | 1 |
| Raimondi, SC | 1 |
| Becton, D | 1 |
| Dahl, GV | 2 |
| Aplenc, R | 1 |
| Alonzo, TA | 1 |
| Gerbing, RB | 1 |
| Lange, BJ | 1 |
| Hurwitz, CA | 1 |
| Wells, RJ | 1 |
| Bernstein, I | 1 |
| Buckley, P | 1 |
| Krimmel, K | 1 |
| Smith, FO | 1 |
| Sievers, EL | 1 |
| Arceci, RJ | 1 |
| Prentice, HG | 2 |
| Robbins, G | 2 |
| Ma, DD | 1 |
| Paciucci, PA | 4 |
| Cuttner, J | 2 |
| Holland, JF | 3 |
| Olsen, GA | 1 |
| Merlin, JL | 1 |
| Missoum, N | 1 |
| Feldmann, L | 1 |
| Marchal, S | 1 |
| Witz, F | 1 |
| Rose, C | 1 |
| Guerci, O | 1 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 1 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Archimbaud, E | 5 |
| Leblond, V | 3 |
| Troussard, X | 3 |
| Jaubert, J | 1 |
| Abubakar, AA | 2 |
| Riches, AC | 2 |
| Schiller, G | 1 |
| Gajewski, J | 1 |
| Lee, M | 1 |
| Ho, W | 1 |
| Territo, M | 1 |
| Champlin, R | 1 |
| Ludescher, C | 1 |
| Eisterer, W | 1 |
| Hilbe, W | 1 |
| Gotwald, M | 1 |
| Hofmann, J | 1 |
| Zabernigg, A | 1 |
| Cianfriglia, M | 1 |
| Thaler, J | 1 |
| Philpott, NJ | 1 |
| Bevan, DH | 1 |
| Gordon-Smith, EC | 1 |
| Schleyer, E | 3 |
| Kamischke, A | 1 |
| Kaufmann, CC | 1 |
| Unterhalt, M | 3 |
| Damon, LE | 1 |
| Rugo, HS | 1 |
| Ries, CA | 1 |
| Linker, CA | 1 |
| Poddubnaia, IV | 1 |
| Perilov, AA | 1 |
| Bhalla, K | 1 |
| Ibrado, AM | 1 |
| Tourkina, E | 1 |
| Tang, C | 1 |
| Grant, S | 1 |
| Bullock, G | 1 |
| Huang, Y | 1 |
| Ponnathpur, V | 1 |
| Mahoney, ME | 1 |
| Genne, P | 1 |
| Duchamp, O | 1 |
| Solary, E | 2 |
| Pinard, D | 1 |
| Belon, JP | 1 |
| Dimanche-Boitrel, MT | 1 |
| Chauffert, B | 1 |
| Ehrhardt, R | 1 |
| Witt, B | 1 |
| Huberts, H | 1 |
| Kaplan, E | 1 |
| Hunstein, W | 1 |
| Reece, DE | 1 |
| Elmongy, MB | 1 |
| Barnett, MJ | 1 |
| Klingemann, HG | 1 |
| Shepherd, JD | 1 |
| Phillips, GL | 1 |
| Béhar, C | 1 |
| Benoit, Y | 1 |
| Robert, A | 1 |
| Vilmer, E | 1 |
| Boutard, P | 1 |
| Bertrand, Y | 1 |
| Lutz, P | 1 |
| Ferster, A | 1 |
| Tokaji, E | 1 |
| Manel, AM | 1 |
| Solbu, G | 2 |
| Otten, J | 1 |
| Gillis, S | 2 |
| Dann, EJ | 1 |
| Rund, D | 1 |
| Chubachi, A | 1 |
| Kuriya, S | 1 |
| Narigasawa, Y | 1 |
| Meguro, K | 1 |
| Endo, K | 1 |
| Takami, H | 1 |
| Sato, S | 1 |
| Sasaki, H | 1 |
| Shiga, T | 1 |
| Maruyama, Y | 1 |
| List, AF | 1 |
| Spier, CS | 1 |
| Grogan, TM | 1 |
| Johnson, C | 1 |
| Roe, DJ | 1 |
| Greer, JP | 1 |
| Wolff, SN | 1 |
| Broxterman, HJ | 2 |
| Dalton, WS | 1 |
| Nelken, B | 1 |
| Landman-Parker, J | 1 |
| Thuret, I | 1 |
| Bergeron, C | 1 |
| Bordigoni, P | 1 |
| Esperou-Bourdeau, H | 1 |
| Schaison, G | 1 |
| Bow, EJ | 1 |
| Sutherland, JA | 1 |
| Kilpatrick, MG | 1 |
| Williams, GJ | 1 |
| Clinch, JJ | 1 |
| Shore, TB | 1 |
| Rubinger, M | 1 |
| Schacter, BA | 1 |
| Nørgaard, JM | 4 |
| Langkjer, ST | 3 |
| Palshof, T | 3 |
| Clausen, N | 2 |
| Pedersen, B | 3 |
| Hokland, P | 4 |
| Klumper, E | 2 |
| Ossenkoppele, GJ | 2 |
| Pieters, R | 2 |
| Huismans, DR | 1 |
| Loonen, AH | 1 |
| Rottier, A | 1 |
| Westra, G | 1 |
| Veerman, AJ | 1 |
| Min, YH | 1 |
| Lee, S | 2 |
| Lee, JW | 1 |
| Chong, SY | 1 |
| Hahn, JS | 1 |
| Ko, YW | 1 |
| Petersen, FB | 1 |
| Bensinger, WI | 1 |
| Fefer, A | 1 |
| Rowley, S | 1 |
| Sanders, J | 1 |
| Chauncey, T | 1 |
| Storb, R | 1 |
| Lilleby, K | 1 |
| Buckner, CD | 1 |
| Chim, CS | 1 |
| Kwong, YL | 1 |
| Cony-Makhoul, P | 2 |
| Tilly, H | 2 |
| Auzanneau, G | 1 |
| Ffrench, M | 2 |
| Olalla, I | 1 |
| Ortín, M | 1 |
| Hermida, G | 1 |
| Cortés, MA | 1 |
| Richard, C | 1 |
| Iriondo, A | 1 |
| Mozota, ML | 1 |
| Zubizarreta, A | 1 |
| Dodge, RK | 2 |
| Amrein, PC | 2 |
| Kolitz, J | 1 |
| Lee, EJ | 3 |
| Powell, B | 1 |
| Godfrey, S | 1 |
| Robert, F | 1 |
| Feldman, EJ | 4 |
| Seiter, K | 3 |
| Linker, C | 1 |
| Rugo, H | 1 |
| Ries, C | 1 |
| Case, DC | 1 |
| Beer, M | 1 |
| Ahmed, T | 3 |
| Wahlin, A | 2 |
| Brinch, L | 1 |
| Hörnsten, P | 2 |
| Evensen, SA | 1 |
| Oberg, G | 1 |
| Hedenus, M | 2 |
| Bailly, JD | 1 |
| Skladanowski, A | 1 |
| Bettaieb, A | 1 |
| Mansat, V | 1 |
| Larsen, AK | 1 |
| Laurent, G | 1 |
| Pförsich, M | 1 |
| Fischer, K | 1 |
| Grey, M | 1 |
| Borg, AG | 1 |
| Wood, P | 1 |
| Burgess, R | 1 |
| Fisher, A | 1 |
| Yin, JA | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Miyamoto, T | 1 |
| Takenaka, K | 1 |
| Tanimoto, K | 1 |
| Mizuno, S | 1 |
| Fujisaki, T | 1 |
| Nagafuji, K | 1 |
| Hayashi, S | 1 |
| Eto, T | 1 |
| Taniguchi, S | 1 |
| Akashi, K | 1 |
| Harada, N | 1 |
| Yamasaki, K | 1 |
| Shibuya, T | 1 |
| Matsuishi, E | 1 |
| Ohno, Y | 1 |
| Makino, S | 1 |
| Takamatsu, Y | 1 |
| Murakawa, M | 1 |
| Teshima, T | 1 |
| Hirota, Y | 1 |
| Okamura, T | 1 |
| Kinukawa, N | 1 |
| Niho, Y | 1 |
| Bukh, A | 1 |
| Haak, H | 1 |
| Stryckmans, P | 1 |
| de Cataldo, R | 1 |
| Dekker, AW | 1 |
| Berneman, ZN | 1 |
| Thyss, A | 1 |
| van der Lelie, J | 1 |
| Visani, G | 5 |
| Hayat, M | 1 |
| Hagemeijer, A | 1 |
| George, SL | 2 |
| Allen, SL | 1 |
| Watkins, LM | 1 |
| Remulla, HD | 1 |
| Rubin, PA | 1 |
| Schumacher, A | 1 |
| Kessler, T | 1 |
| Wewers, D | 1 |
| van de Loo, J | 1 |
| Stevens, RF | 1 |
| Gray, RG | 1 |
| Dissing, M | 1 |
| Le Beau, MM | 1 |
| Pedersen-Bjergaard, J | 1 |
| Sousa, AB | 1 |
| Fernandes, JP | 1 |
| Costa, I | 1 |
| Ferreira, G | 1 |
| Nunes, O | 1 |
| Ribeiro, P | 1 |
| Neves, A | 1 |
| Cruz, E | 1 |
| Aveiro, F | 1 |
| Rodrigues, AS | 1 |
| Bernardo, M | 1 |
| Conduto, A | 1 |
| Gonçalves, AJ | 1 |
| Monteiro, A | 1 |
| Sousa, M | 1 |
| Soares, VH | 1 |
| Veiga, J | 1 |
| Gouveia, J | 1 |
| Bassan, R | 1 |
| Lerede, T | 1 |
| Buelli, M | 1 |
| Borleri, G | 1 |
| Bellavita, P | 1 |
| Rambaldi, A | 1 |
| Barbui, T | 1 |
| Maschmeyer, G | 3 |
| Schönrock-Nabulsi, R | 1 |
| Bartholomäus, A | 1 |
| Bettelheim, P | 1 |
| Kuse, R | 1 |
| Kerkhoff, A | 1 |
| Grote-Metke, A | 1 |
| Kubica, U | 1 |
| Schuurhuis, GJ | 1 |
| Baak, JP | 1 |
| Eekman, CA | 1 |
| Kuiper, CM | 1 |
| Feller, N | 1 |
| van Heijningen, TH | 1 |
| Senent, L | 1 |
| Jarque, I | 1 |
| Martín, G | 1 |
| Sempere, A | 1 |
| González-García, Y | 1 |
| Gomis, F | 1 |
| Pérez-Sirvent, M | 1 |
| De La Rubia, J | 1 |
| Sanz, MA | 1 |
| Ozkaynak, MF | 1 |
| Avramis, VI | 1 |
| Carcich, S | 1 |
| Ortega, JA | 1 |
| Navarro, JT | 1 |
| Hernández, JA | 1 |
| Sancho, JM | 1 |
| Pujol, M | 1 |
| Millá, F | 1 |
| Advani, R | 1 |
| Saba, HI | 1 |
| Tallman, MS | 2 |
| Rowe, JM | 2 |
| Wiernik, PH | 3 |
| Ramek, J | 1 |
| Dugan, K | 1 |
| Lum, B | 1 |
| Villena, J | 1 |
| Davis, E | 1 |
| Paietta, E | 2 |
| Litchman, M | 1 |
| Sikic, BI | 3 |
| Greenberg, PL | 1 |
| Bennett, JM | 2 |
| Lemoli, RM | 2 |
| Leopardi, G | 2 |
| Motta, MR | 2 |
| Rizzi, S | 3 |
| Testoni, N | 3 |
| Curti, A | 1 |
| Tura, S | 4 |
| Martino, R | 1 |
| Altés, A | 1 |
| Sureda, A | 1 |
| De Cataldo, F | 1 |
| Belhabri, A | 1 |
| Peaud, PY | 1 |
| Martin, C | 1 |
| Oelschlägel, U | 1 |
| Nowak, R | 1 |
| Renner, U | 1 |
| Ziegs, B | 1 |
| Subat, S | 1 |
| Delair, S | 1 |
| Simon, M | 1 |
| Nicolini, F | 1 |
| Stoppa, AM | 1 |
| Janvier, M | 1 |
| Bordessoule, D | 1 |
| Rousselot, P | 1 |
| Raanani, P | 1 |
| Shpilberg, O | 1 |
| Avigdor, A | 1 |
| Hardan, I | 1 |
| Berkowicz, M | 1 |
| Sofer, O | 1 |
| Lossos, I | 1 |
| Chetrit, A | 1 |
| Ben-Yehuda, D | 1 |
| Ben-Bassat, I | 1 |
| Karanes, C | 1 |
| Head, DR | 2 |
| Grever, MR | 1 |
| Hynes, HE | 1 |
| Kraut, EH | 2 |
| Vial, RH | 1 |
| Nand, S | 1 |
| Samlowski, WE | 1 |
| Lemoli, R | 1 |
| Tosi, P | 1 |
| Martinelli, G | 3 |
| Ricci, P | 1 |
| Motta, M | 1 |
| Gherlinzoni, F | 1 |
| Pastano, R | 1 |
| Piccaluga, P | 1 |
| Isidori, A | 3 |
| Witz, B | 1 |
| Lioure, B | 1 |
| Hunault-Berger, M | 1 |
| Desablens, B | 1 |
| Delain, M | 1 |
| Guilhot, F | 1 |
| Le Prise, PY | 1 |
| Abgrall, JF | 1 |
| Deconinck, E | 1 |
| Guyotat, D | 1 |
| Vilque, JP | 1 |
| Casassus, P | 1 |
| Tournilhac, O | 1 |
| Audhuy, B | 1 |
| Traganos, F | 1 |
| Darzynkiewicz, Z | 2 |
| Goff, H | 1 |
| Pozzuoli, M | 2 |
| Baskind, P | 1 |
| Santos, S | 1 |
| Chauncey, TR | 1 |
| Rankin, C | 1 |
| Chen, I | 1 |
| Godwin, JE | 1 |
| Kalaycio, ME | 1 |
| Moore, DF | 1 |
| Shurafa, MS | 1 |
| Petersdorf, SH | 1 |
| Leith, CP | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Treleaven, J | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Ashley, S | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Haase, D | 1 |
| Fonatsch, C | 1 |
| Löffler, H | 1 |
| Schlegelberger, B | 1 |
| Keane, FM | 1 |
| Munn, SE | 1 |
| Buckley, DA | 1 |
| Hopster, D | 1 |
| Mufti, GJ | 1 |
| du Vivier, AW | 1 |
| Bernasconi, P | 1 |
| Boni, M | 1 |
| Castoldi, GL | 1 |
| Ciolli, S | 1 |
| Clavio, M | 1 |
| Cox, MC | 1 |
| Cuneo, A | 1 |
| Dini, D | 1 |
| Falzetti, D | 1 |
| Fanin, R | 1 |
| Gobbi, M | 1 |
| Leoni, F | 1 |
| Malagola, M | 2 |
| Mecucci, C | 1 |
| Piccaluga, PP | 2 |
| Rondelli, R | 1 |
| Russo, D | 1 |
| Sessarego, M | 1 |
| Torelli, G | 1 |
| Sreekantaiah, C | 1 |
| Weisberger, J | 1 |
| Liu, D | 1 |
| Papageorgio, C | 1 |
| Weiss, M | 1 |
| Kancherla, R | 1 |
| Kimby, E | 1 |
| Nygren, P | 1 |
| Glimelius, B | 1 |
| Berg, DT | 1 |
| Schulman, PP | 1 |
| Wittmer, E | 1 |
| Ohnesorge, J | 1 |
| Gugliotta, L | 1 |
| Bonini, A | 1 |
| Bonifazi, F | 1 |
| Castellani, S | 1 |
| Wulf, GG | 1 |
| Wang, RY | 1 |
| Kuehnle, I | 1 |
| Weidner, D | 1 |
| Brenner, MK | 1 |
| Goodell, MA | 1 |
| Goldstone, AH | 1 |
| Burnett, AK | 1 |
| Smith, AG | 1 |
| Hutchinson, RM | 3 |
| Clark, RE | 1 |
| Indrák, K | 1 |
| Hubácek, J | 1 |
| Voglová, J | 1 |
| Jarosová, M | 1 |
| Krahulová, M | 1 |
| Malý, J | 1 |
| Faber, E | 1 |
| Penka, M | 1 |
| Kmonícek, M | 1 |
| Jebavý, L | 1 |
| Szotkowski, T | 1 |
| Knotková, R | 1 |
| Hlusí, A | 1 |
| Zapletalová, J | 1 |
| Stadheim, TA | 1 |
| Kucera, GL | 1 |
| Olesen, LH | 1 |
| Olesen, G | 1 |
| Meyer, K | 1 |
| Kristensen, JS | 1 |
| Bendix, K | 1 |
| Kjeldsen, E | 1 |
| van der Kolk, DM | 1 |
| Vellenga, E | 1 |
| Müller, M | 1 |
| Bates, SE | 1 |
| de Vries, EG | 1 |
| Lacayo, NJ | 1 |
| Lum, BL | 1 |
| Becton, DL | 1 |
| Weinstein, H | 1 |
| Bomgaars, L | 1 |
| Lauer, SJ | 1 |
| Elson, P | 1 |
| Hussein, M | 1 |
| Andresen, S | 1 |
| Manoharan, A | 1 |
| Trickett, A | 1 |
| Kwan, YL | 1 |
| Brighton, T | 1 |
| Hon, C | 1 |
| Shek, TW | 1 |
| Liang, R | 2 |
| Seshi, B | 1 |
| Kashyap, A | 1 |
| Parker, AN | 1 |
| Chapman, CS | 1 |
| Bosanquet, AG | 1 |
| Winfield, DA | 1 |
| Harker, WG | 1 |
| Slade, DL | 1 |
| Drake, FH | 1 |
| Parr, RL | 1 |
| Liu Yin, JA | 1 |
| Johnson, PR | 1 |
| Davies, JM | 1 |
| Flanagan, NG | 1 |
| Gorst, DW | 1 |
| Lewis, MJ | 1 |
| Ohno, R | 1 |
| Yokomaku, S | 1 |
| Okumura, M | 1 |
| Nagai, T | 1 |
| Kitaori, K | 1 |
| Ito, T | 1 |
| Takeo, T | 1 |
| Sugiura, I | 1 |
| Yano, K | 1 |
| Ito, Y | 1 |
| Frisch, J | 1 |
| Zühlsdorf, M | 2 |
| Rottmann, R | 1 |
| Boeckmann, A | 2 |
| Reuter, C | 1 |
| Freire, EA | 2 |
| Innig, G | 2 |
| Schulz, G | 1 |
| Koenigsmann, M | 1 |
| Malm, C | 1 |
| Del Bino, G | 1 |
| Rosenthal, NS | 1 |
| Farhi, DC | 1 |
| Jungerová, J | 1 |
| Koza, V | 1 |
| Cepelák, V | 1 |
| Chiu, E | 1 |
| Chan, TK | 1 |
| Todd, D | 1 |
| Ohnuma, T | 1 |
| Arkin, H | 1 |
| Chan, HS | 1 |
| Estrov, Z | 1 |
| Weitzman, SS | 1 |
| Freedman, MH | 1 |
| Chitnis, MP | 3 |
| Satyamoorthy, K | 1 |
| Pradhan, SG | 1 |
| Advani, SH | 3 |
| Kantarjian, HM | 1 |
| Walters, RS | 1 |
| Keating, MJ | 1 |
| Talpaz, M | 1 |
| Andersson, B | 1 |
| Beran, M | 1 |
| McCredie, KB | 1 |
| Freireich, EJ | 1 |
| Heinemann, V | 1 |
| Murray, D | 1 |
| Walters, R | 1 |
| Meyn, RE | 1 |
| Plunkett, W | 1 |
| Juvekar, AS | 2 |
| Adwankar, MK | 1 |
| Okuma, K | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Sampi, K | 1 |
| Ogawa, M | 1 |
| Kimura, I | 1 |
| Ohnoshi, T | 1 |
| Yamada, K | 1 |
| Masaoka, T | 1 |
| Wakui, A | 1 |
| Meguro, S | 1 |
| Nagai, K | 1 |
| Kitani, T | 1 |
| Keaveney, C | 1 |
| Steuber, CP | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Ragab, AH | 1 |
| Krischer, J | 1 |
| Vietti, TJ | 1 |
| Arlin, ZA | 2 |
| Silver, R | 1 |
| Cassileth, P | 2 |
| Armentrout, S | 1 |
| Gams, R | 2 |
| Daghestani, A | 1 |
| Coleman, M | 1 |
| Schoch, I | 2 |
| Dukart, G | 2 |
| Meyer, P | 2 |
| Mjaaland, I | 2 |
| Heidemann, E | 1 |
| Seither, E | 2 |
| Reisman, A | 1 |
| Moore, J | 1 |
| Silver, RA | 1 |
| Bertino, J | 1 |
| Wimperis, JZ | 1 |
| Ostendorf, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC[NCT00052299] | Phase 3 | 472 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL[NCT00002549] | Phase 3 | 1,520 participants (Anticipated) | Interventional | 1993-11-30 | Active, not recruiting | ||
| [NCT01674985] | Phase 1/Phase 2 | 43 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia[NCT00143975] | Phase 2 | 95 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients[NCT00048958] | 9,000 participants (Anticipated) | Observational | 1984-06-30 | Active, not recruiting | |||
| Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission[NCT01050036] | 39 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | |||
| ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1994-01-31 | Active, not recruiting | ||
| RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)[NCT00002719] | Phase 3 | 500 participants (Anticipated) | Interventional | 1995-12-31 | Completed | ||
| Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML[NCT00880243] | Phase 3 | 473 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia[NCT00028899] | Phase 1 | 47 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162] | Phase 3 | 580 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals With Relapsed/Refractory Multiple Myeloma[NCT05956457] | 100 participants (Anticipated) | Interventional | 2023-07-20 | Recruiting | |||
| A Pilot Study of Tc-94m Sestamibi PET MDR Imaging[NCT00082368] | Phase 2 | 12 participants (Actual) | Interventional | 2004-05-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00082368)
Timeframe: 69 months
| Intervention | participants (Number) |
|---|---|
| PET Imaging With Tc-94m Sestamibi | 8 |
Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. Significant increase in the SUV in tumor is +25% over baseline. (NCT00082368)
Timeframe: 3 days
| Intervention | % change in Tc-94m Sestamibi SUVmax (Mean) |
|---|---|
| PET Imaging With Tc-94m Sestamibi | 44 |
9 reviews available for mitoxantrone and Leukemia, Myeloid
| Article | Year |
|---|---|
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Child; Chromosome Aberrations; Clinical Tri | 2003 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 2003 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
High-dose mitoxantrone in acute leukaemia: New York Medical College experience.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Cl | 1997 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromoso | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2001 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin | 1991 |
78 trials available for mitoxantrone and Leukemia, Myeloid
| Article | Year |
|---|---|
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; De | 2017 |
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Che | 2009 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ca | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunor | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2009 |
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytar | 2011 |
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidi | 2010 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, N | 2002 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 2002 |
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug | 2002 |
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2002 |
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Topics: Acute Disease; Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cytara | 2003 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eto | 2003 |
Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2004 |
Maintenance therapy in childhood acute myeloid leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow | 2004 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resis | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziri | 2005 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunoru | 2005 |
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2005 |
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2005 |
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; | 2005 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyta | 2006 |
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytar | 2006 |
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chem | 2006 |
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2007 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anti | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2006 |
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Di | 2007 |
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2007 |
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2007 |
[The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; | 2007 |
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2008 |
Mitoxantrone in relapsed and refractory acute leukemia.
Topics: Acute Disease; Aged; Anthraquinones; Antineoplastic Agents; Cell Line; Clinical Trials as Topic; Fol | 1984 |
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combin | 1984 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Clinical Trials as Topic; Drug Ad | 1984 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etopos | 1993 |
Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1993 |
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dis | 1996 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administratio | 1995 |
Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation | 1996 |
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1996 |
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1996 |
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoq | 1997 |
A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Proto | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Co | 1997 |
High-dose mitoxantrone in acute leukaemia: New York Medical College experience.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Cl | 1997 |
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug | 1998 |
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinone | 1998 |
Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -- a longitudinal study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1998 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over | 1998 |
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; | 1998 |
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Critical Car | 1998 |
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1999 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemoth | 1999 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Divisio | 1999 |
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1999 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; | 2000 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 2000 |
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Disease-Free Surv | 2000 |
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2001 |
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
Topics: Actuarial Analysis; Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dau | 2001 |
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
Topics: Acute Disease; Aged; Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloi | 2001 |
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; | 2002 |
Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cytarabine; | 2002 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin | 1991 |
In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cyt | 1991 |
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1991 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone | 1985 |
102 other studies available for mitoxantrone and Leukemia, Myeloid
| Article | Year |
|---|---|
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cytarabine; Fatty A | 2015 |
Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child | 2011 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2012 |
Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leuka
Topics: Anthraquinones; Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Heterocyclic C | 2012 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; | 2012 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigen | 2002 |
Low levels of ABCG2 expression in adult AML blast samples.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member | 2002 |
Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administratio | 2003 |
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria; Chi | 2004 |
Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Cells; CD13 | 2004 |
Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2003 |
The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.
Topics: Acute Disease; Adult; Aged; Daunorubicin; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane | 2003 |
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabi | 2004 |
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport | 2004 |
Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Antigens, CD; Antigens, CD34 | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell | 2005 |
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2005 |
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chro | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chro | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chro | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chro | 2005 |
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Topics: Acute Disease; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 2005 |
Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2005 |
[What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromoso | 2005 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Breast Neoplas | 2007 |
Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2006 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; | 2007 |
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Child, Preschool; D | 2008 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot | 1995 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1995 |
Mitoxantrone treatment of murine myeloid leukaemia sublines.
Topics: Animals; Bone Marrow; Female; Leukemia, Myeloid; Mice; Mice, Inbred CBA; Mitoxantrone; Neoplasm Tran | 1995 |
Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chem | 1994 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; F | 1993 |
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Topics: Acute Disease; Adult; Carboxylic Acids; Half-Life; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B | 1994 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytara | 1993 |
High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.
Topics: Apoptosis; Cytarabine; DNA; Dose-Response Relationship, Drug; Genes, jun; Genes, myc; Humans; Leukem | 1993 |
Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.
Topics: Antineoplastic Agents; Blood Proteins; Cinchona Alkaloids; Doxorubicin; Drug Interactions; Drug Resi | 1994 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Inf | 1996 |
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla | 1996 |
Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents; Cell Differentiation; Cell Survival; Ch | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine | 1996 |
Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance, | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Diseases; Cytarabin | 1996 |
Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Co | 1996 |
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1997 |
A possible correlation between growth-factor sensitivity and response to mitoxantrone treatment in a murine myeloid leukaemia (SA7HD) cell line.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Count; Cell Division; Culture Media, Conditioned; | 1997 |
Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis.
Topics: Acute Disease; Apoptosis; Biological Transport; Cell Cycle; Cell Differentiation; Cell Survival; Deo | 1997 |
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporte | 1997 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resis | 1998 |
Orbital granulocytic sarcoma in an elderly patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Exophthalmos; Female; Humans; Immunoenzyme Tec | 1997 |
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inv | 1998 |
Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1998 |
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Sub | 1995 |
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclona | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Antineopl | 1999 |
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationshi | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone | 1999 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Hu | 2000 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etop | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Co | 2001 |
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Ant | 2001 |
c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blotting, Western; DNA, Neoplasm; Flavonoids; HL-60 Ce | 2002 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplas | 2001 |
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Ca | 2002 |
Conjunctival chloroma (granulocytic sarcoma).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Conjunctival Neoplasms; Etoposide; Humans; Leu | 2002 |
Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Topics: Acid Phosphatase; Acute Disease; Alkaline Phosphatase; Antigens, CD; Antigens, Differentiation, Myel | 1992 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etopos | 1992 |
Mitozantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloid leukaemia. Trent Working Party on Adult Leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1992 |
Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Topics: Catalysis; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type | 1991 |
Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1991 |
Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leuke
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; | 1991 |
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytar | 1991 |
Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Topics: Amsacrine; Camptothecin; Cell Line; DNA; Doxorubicin; Humans; In Vitro Techniques; Leukemia, Myeloid | 1991 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorub | 1991 |
[Injections of mitoxantrone, VUFB Praha, in the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma].
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelo | 1991 |
Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug R | 1991 |
Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect).
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Carboplatin; Cell Count; Cell Survival; Cisplati | 1986 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubi | 1987 |
Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil.
Topics: Antidepressive Agents, Tricyclic; Colony-Forming Units Assay; Dibenzoxazepines; DNA Replication; Dru | 1988 |
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leu | 1988 |
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Ne | 1988 |
Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia.
Topics: Antineoplastic Agents; Cell Survival; Combined Modality Therapy; DNA Replication; Hot Temperature; H | 1986 |
[Cardiotoxicity of mitoxantrone].
Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart | 1986 |
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Blast Crisis; Child; Daunorubicin; Drug Evaluat | 1986 |
In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells.
Topics: Cell Survival; Diazepam; Doxorubicin; Hot Temperature; Humans; In Vitro Techniques; Leukemia, Myeloi | 1987 |
Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; | 1987 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea | 1987 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem | 1985 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow | 1985 |
Phase I-II trial of mitoxantrone in acute leukemia: an interim report.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Digestive System; Drug Evaluation | 1985 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Female; Humans | 1985 |